Contraindications and Side Effects of Iron Infusion

Absolute Contraindications

Active severe infection is the primary contraindication for intravenous iron therapy, as it can be harmful in the presence of severe infection, and should be used with extreme caution, if at all, in patients with active infection 1, 2
Patients with prior serious reactions to parenteral iron products should not receive the same formulation, and iron dextran carries a boxed FDA warning regarding anaphylaxis risk and requires a test dose prior to full administration 3

Infusion-related adverse events occur in approximately 4.3% of patients receiving intravenous iron, including anaphylactoid reactions, hypotension, shortness of breath, chills, and flushing 1, 2, 4
Iron dextran (especially high-molecular-weight formulations) carries the highest risk of anaphylactoid reactions compared to non-dextran preparations like ferric gluconate or iron sucrose 1, 3

True anaphylaxis is very rare but potentially life-threatening, and resuscitation facilities must be available when administering IV iron, with patients monitored for 60 minutes after initial infusion 3, 5

Iron dextran requires special precautions, including a mandatory test dose before full administration, due to its higher incidence of severe reactions compared to non-dextran formulations 1, 3, 6
Non-dextran preparations (iron sucrose, ferric gluconate, ferric carboxymaltose) have a lower risk of anaphylactoid reactions, but ferric carboxymaltose has a unique hypophosphatemia risk 1, 3

Before administration, screen for active infection, obtain history of prior reactions to parenteral iron, and ensure resuscitation equipment is immediately available 1, 2, 5
During infusion, monitor vital signs and observe for signs of hypersensitivity, and have emergency medications readily accessible 5
Post-infusion, observe for at least 60 minutes after initial dose, monitor phosphate levels when using ferric carboxymaltose, and avoid iron overload by monitoring transferrin saturation and ferritin 5, 6

Intravenous iron increases the incidence of new infections by 16 % relative to control (risk ratio = 1.16; 95 % CI 1.03–1.29), corresponding to approximately 16 additional infections per 1,000 treated patients; this estimate is based on moderate‑quality evidence from a meta‑analysis of 154 randomized trials involving 32,762 participants. 7

The majority of adverse reactions to intravenous iron are complement activation‑related pseudo‑allergies (CARPA) rather than true IgE‑mediated anaphylaxis, occurring in about 4.3 % of patients receiving iron infusions. 8
True anaphylaxis after intravenous iron is very rare but can be life‑threatening; iron dextran formulations carry an FDA boxed warning for this risk and require a mandatory test dose before full administration. 8
Clinical guidance emphasizes that CARPA reactions should be managed as infusion‑related hypersensitivity rather than anaphylaxis, and epinephrine is not required as first‑line treatment in most cases. 8

Iron dextran (especially high‑molecular‑weight preparations) has the highest risk of hypersensitivity and anaphylactoid reactions among intravenous iron products, necessitating a test dose and heightened monitoring. 8